RANBAXY RECEIVES APPROVAL TO MARKET RANTM-PRAVASTATIN IN CANADA

May 21, 2007

Toronto, ON, Canada - Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval in Canada to manufacture and market RanTM-Pravastatin Tablets, 10 mg, 20 mg, and 40 mg, from Health Canada, Therapeutic Products Directorate (TPD). Total annual market sales for Pravastatin in Canada is CAD $72.9 million (IMS-MAT: March 2007). Pravastatin is indicated as an adjunct to diet for the reduction of elevated total and low density lipoprotein cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb), in hypercholesterolemic patients without clinically evident coronary heart disease, and in patients with total cholesterol in the normal to moderately elevated range who have clinically evident coronary heart disease. “We are pleased to receive this approval for RANTM-Pravastatin to expand the number of product offerings that Ranbaxy commercializes in Canada. This molecule will add breadth to our expanding generic product portfolio that offers affordable generic alternatives to the brand that will now be accessible to all Canadians. We anticipate product being available by June 2007 to all classes of trade,” said Paul Drake, President and General Manager, RPCI. He further added, “Ranbaxy’s presence in Canada was established in the latter part of 2005, and our efforts to expand our business was fueled through inorganic product strategies. This approval is based on our organic product strategy, that utilizes the internal R&D expertise and capabilities of our parent company, Ranbaxy Laboratories Limited. Going forward, this will become the primary pathway for future additions to our basket of products.” Ranbaxy Pharmaceuticals-Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system. Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries. For further information please contact: Paul Drake, President and General Manager, Ranbaxy Pharmaceuticals Canada Inc. 905-219-8840 or Charles M. Caprariello Vice President, Corporate Communications Ranbaxy Inc. (609) 720-5615 or Ramesh L. Adige Executive Director- Corporate Affairs and Global Corporate Communications Ranbaxy Laboratories Ltd. Plot 90, Sector 32, Gurgaon Haryana 122001, India Tel: +91-124-4135000 e-mail: ramesh.adige@ranbaxy.com or Raghu Kochar Director-Corporate Communications Ranbaxy Laboratories Ltd. Plot 90, Sector 32, Gurgaon Haryana 122001, India Tel: +91-124-4135141 Mobile: 9811617256 e-mail: raghu.kochar@ranbaxy.com or Krishnan Ramalingam Sr.Manager- Corporate Communications Plot 90, Sector 32, Gurgaon Haryana 122001, India Tel: +91-124-4135143 Mobile: 9810042540 e-mail: krishnan.ramalingam@ranbaxy.com